End Points for Clinical Trials in Primary Hyperoxaluria
- 12 March 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 15 (7) , 1056-1065
Abstract
Patients with primary hyperoxaluria experience kidney stones from a young age and can develop progressive oxalate nephropathy. Progression to kidney failure often develops over a number of years, and is associated with systemic oxalosis, intensive dialysis, and often combined kidney and liver transplantation. There are no therapies approved by the Food and Drug Association. Thus, the Kidney Health Initiative, in partnership with the Oxalosis and Hyperoxaluria Foundation, initiated a project to identify end points for clinical trials. A workgroup of physicians, scientists, patients with primary hyperoxaluria, industry, and United States regulators critically examined the published literature for clinical outcomes and potential surrogate end points that could be used to evaluate new treatments. Kidney stones, change in eGFR, urine oxalate, and plasma oxalate were the strongest candidate end points. Kidney stones affect how patients with primary hyperoxaluria feel and function, but standards for measurement and monitoring are lacking. Primary hyperoxaluria registry data suggest that eGFR decline in most patients is gradual, but can be unpredictable. Epidemiologic data show a strong relationship between urine oxalate and long-term kidney function loss. Urine oxalate is reasonably likely to predict clinical benefit, due to its causal role in stone formation and kidney damage in CKD stages 1–3a, and plasma oxalate is likely associated with risk of systemic oxalosis in CKD 3b–5. Change in slope of eGFR could be considered the equivalent of a clinically meaningful end point in support of traditional approval. A substantial change in urine oxalate as a surrogate end point could support traditional approval in patients with primary hyperoxaluria type 1 and CKD stages 1–3a. A substantial change in markedly elevated plasma oxalate could support accelerated approval in patients with primary hyperoxaluria and CKD stages 3b–5. Primary hyperoxaluria type 1 accounts for the preponderance of available data, thus heavily influences the conclusions. Addressing gaps in data will further facilitate testing of promising new treatments, accelerating improved outcomes for patients with primary hyperoxaluria.Keywords
Funding Information
- KHI
- U.S. Food and Drug Administration
- RKSC
- National Institute of Diabetes and Digestive and Kidney Diseases (U54DK083908)
- National Center for Advancing Translational Sciences
- National Institutes of Health
- Oxalosis and Hyperoxaluria Foundation
This publication has 49 references indexed in Scilit:
- Fostering Innovation, Advancing Patient SafetyClinical Journal of the American Society of Nephrology, 2013
- Four of the Most Common Mutations in Primary Hyperoxaluria Type 1 Unmask the Cryptic Mitochondrial Targeting Sequence of Alanine:glyoxylate Aminotransferase Encoded by the Polymorphic Minor AlleleJournal of Biological Chemistry, 2013
- Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretionJournal of Clinical Investigation, 2012
- Transplantation Outcomes in Primary HyperoxaluriaAmerican Journal of Transplantation, 2010
- Excellent renal function and reversal of nephrocalcinosis 8 years after isolated liver transplantation in an infant with primary hyperoxaluria type 1Pediatric Nephrology, 2010
- Evolution of Causes and Risk Factors for Mortality Post‐Liver Transplant: Results of the NIDDK Long‐Term Follow‐Up StudyAmerican Journal of Transplantation, 2010
- Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1Kidney International, 2009
- Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failureKidney International, 1999
- Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluriaKidney International, 1998
- Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failureKidney International, 1995